NSCLC cells were pretreated with HER3 selective inhibitor TX1-85-1, AKT selective inhibitor perifosine or NF-κB selective inhibitor JSH23, then treated with osimertinib. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.